About
The Dementia Discovery Fund (DDF) is a specialized venture capital fund that exclusively invests in companies developing novel therapeutics for dementia. Established in 2015 and managed by SV Health Investors, DDF aims to accelerate the development of groundbreaking therapies for neurodegenerative diseases, including Alzheimer's. It focuses on early-stage projects, from new target identification to translating biological insights into disease-modifying drugs. DDF has offices in London and Boston and has raised over $600 million across its funds. They invest in and build biotech companies, providing strategic investment and industry expertise. The fund's limited partners include major pharmaceutical companies, financial institutions, and charities.
Portfolio · 1
Investment activity
Portfolio by sector
Q&A
- What is Dementia Discovery Fund's primary investment focus?
- Dementia Discovery Fund primarily invests in the Health Tech & Life Sciences sector, with a focus on therapeutics for neurodegenerative diseases.
- Can you name a notable company in Dementia Discovery Fund's portfolio?
- Mitoconix Bio, a company developing therapeutics for neurodegenerative diseases, is a notable company in Dementia Discovery Fund's portfolio.
- What was Dementia Discovery Fund's most recent investment activity?
- Dementia Discovery Fund participated in a Series A round for Mitoconix Bio in June 2017, which raised $20M.
- What stage investments does Dementia Discovery Fund typically make?
- Dementia Discovery Fund has participated in A Round investments, such as the $20M Series A for Mitoconix Bio.
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
Identifiers & details
| Founded | 2015 |
|---|